Original Article

Biotechnology and Drug Discovery: From Bench to Bedside

Authors: Yoav Avidor, MD, MBA, Nicola J. Mabjeesh, MD, PHD, Haim Matzkin, MD

Abstract

New biotechnology and drug discovery technologies are facilitating the rapid expansion of the clinical drug chest, empowering clinicians with a better understanding of disease as well as novel modalities for treating patients. Important research tools and themes include genomics, proteomics, ligand-receptor interaction, signal transduction, rational drug design, biochips, and microarrays. Emerging drug classes include monoclonal antibodies, cancer vaccines, gene therapy, antisense strands, enzymes, and proteins. In this article, we review these topics and illustrate their potential impact by presenting an overview of promising drugs in the pipeline. Clinicians who use these novel treatments must become familiar with these trends.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Cunningham MJ. Genomics and proteomics: The new millennium of drug discovery and development. J Pharmacol Toxicol Methods 2000; 44: 291–300.
 
2. Greenbaum D, Luscombe NM, Jansen R, Qian J, Gerstein M. Interrelating different types of genomic data, from proteome to secretome: ‘oming in on function. Genome Res 2001; 11: 1463–1468.
 
3. Sebti SM, Hamilton AD. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene 2000; 19: 6566–6573.
 
4. Jain KK. Biochips for gene spotting. Science 2001; 294: 621–623.
 
5. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000; 289: 1760–1763.
 
6. Blundell TL. Structure-based drug design. Nature 1996; 384: 23–26.
 
7. Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999; 35: 2010–2030.
 
8. Savage DG, Antman KH. Imatinib mesylate: A new oral targeted therapy. N Engl J Med 2002; 346: 683–693.
 
9. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 2001; 20: 5054–5058.
 
10. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493–502.
 
11. de Bono JS, Rowinsky EK. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 2002; 8: S19–26.
 
12. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 1998; 16 2964–2976.
 
13. Crowell JA, Goldenthal EI, Kelloff GJ, Malone WF, Boone CW. Chronic toxicity studies of the potential cancer preventive 2-(difluoromethyl)-dl-ornithine. Fundam Appl Toxicol 1994; 22 341–354.
 
14. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8 128–135.
 
15. Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol 2001; 41 397–403.
 
16. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001; 28 613–619.
 
17. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20 4420–4427.
 
18. Alberts DS, Hallum AV III. Stratton-Custis M, Garcia DJ, Gleason-Guzman M, Salmon SE, et al. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A) a novel oral biphosphonate anticancer drug. Clin Cancer Res 2001; 7: 1246–1250.
 
19. Zhai S, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002;; 36: 905–911.
 
20. George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59: 2395–2401.
 
21. Goss PE, Baker MA, Carver JP, Dennis JW. Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin Cancer Res 1995; 1: 935–944.
 
22. Monga M, Sausville EA. Developmental therapeutics program at the NCI: Molecular target and drug discovery process. Leukemia 2002; 16: 520–526.
 
23. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885–4892.
 
24. D’Amato RJ, Loughnan MS, Flynn E, Folkma J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082–4085.
 
25. Wilkinson D, Murray J. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 852–857.
 
26. Gingras D, Renaud A, Mousseau N, Beliveau R. Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills? Cancer Metastasis Rev 2000; 19: 83–86.
 
27. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001; 21: 145–155.
 
28. Workman P, Maloney A. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002; 2: 3–24.
 
29. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24: 163–169.
 
30. Hughes RA, Harris T, Altmann E, McAlliste D, Vlahos R, Robertson A, et al. 2-Methoxyestradiol and analogs as novel antiproliferative agents: Analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding. Mol Pharmacol 2002; 61: 1053–1069.
 
31. Koths K. Recombinant proteins for medical use: The attractions and challenges. Curr Opin Biotechnol 1995; 6: 681–687.
 
32. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: New approaches to treatment. Oncologist 2000; 5: 162–168.
 
33. Wild JS, Hyde DM, Hubbell HR, Giri SN. Dose-related effects of Ampligen (poly(I).poly(C12U)), a mismatched double-stranded RNA, in a bleomycin-mouse model of pulmonary fibrosis. Exp Lung Res 1996; 22: 375–391.
 
34. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17–23.
 
35. Chirigos MA, Talor E, Sidwell RW, Burger RA, Warren RP. Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol 1995; 17: 247–264.
 
36. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL). Crit Rev Oncol Hematol 2001; 40: 37–51.
 
37. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39: 798–803.
 
38. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure: Nesiritide Study Group. N Engl J Med 2000; 343: 246–253.
 
39. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM,et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J Immunol 2002; 168: 4462–4471.
 
40. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248–255.
 
41. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052–2058.
 
42. Piascik P. Omalizumab: A novel monoclonal antibody for treatment of allergic disease. J Am Pharm Assoc (Wash) 2002; 42: 356–358.
 
43. Leonard JP, Link BK. Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 2002; 29: 81–86.
 
44. Harwood SJ, Gibbons LK, Goldner PJ, Webster WB, Carroll RG. Outpatient radioimmunotherapy with Bexxar: Closed, clean air reservoir minimizes personnel radiation exposure. Cancer 2002;; 94( 4 Suppl): 1358–1362.
 
45. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn’s disease. Gastroenterology 2001; 121: 268–274.
 
46. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999; 52: 1072–1074.
 
47. Linn JF, Black P, Derksen K, Rubben H, Thuroff JW. Keyhole limpet haemocyanin in experimental bladder cancer: Literature review and own results. Eur Urol 2000; 37( Suppl 3): 34–40.
 
48. McNeil C. Monoclonal antibodies progress to the next generation. J Natl Cancer Inst 1995; 87: 1738–1739.
 
49. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735–740.
 
50. King KM, Younes A. Rituximab: Review and clinical applications focusing on non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther 2001; 1: 177–186.
 
51. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin Oncol 2002; 29( 1 Suppl 2): 105–112.
 
52. Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: The clinical experience with infliximab (REMICADE). Int J Clin Pract 2001; 55: 211–216.
 
53. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol 2001; 96: 722–729.
 
54. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.
 
55. Pastore RD, Pfeffer LM, Nanus DM. Renal cell carcinoma and interferon at the millennium. Cancer Invest 2001; 19: 281–291.
 
56. Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000; 74: 41–44.
 
57. Zanussi S, De Paoli P. The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients. Biomed Pharmacother 2000; 54: 316–320.
 
58. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, et al. Outpatient biochemotherapy with interleukin-2 and interferon α-2b in patients with metastatic malignant melanoma: Results of two Phase II cytokine working group trials. J Clin Oncol 2001; 19: 3194–3202.
 
59. Ahmed A, Keeffe EB. Hepatitis C virus and liver transplantation. Clin Liver Dis 2001; 5: 1073–1090.
 
60. Haas GP, Hillman GG. Update on the role of immunotherapy in the management of kidney cancer. Cancer Control 1996; 3: 536–541.
 
61. Dempke W, Von Poblozki A, Grothey A, Schmoll HJ. Human hematopoietic growth factors: Old lessons and new perspectives. Anticancer Res 2000; 20: 5155–5164.
 
62. Duhrsen U. The clinical value of erythropoietin in patients with cancer. Drugs 2002; 62: 2013–2023.
 
63. Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol 2001; 21: 190–203.
 
64. Anderson WF. Human gene therapy. Nature 1998; 392: 25–30.
 
65. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001; 38: 177–192.
 
66. Wilson JM. Vectors: Shuttle vehicles for gene therapy. Clin Exp Immunol 1997; 107( Suppl 1: 31–32.
 
67. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000; 301: 143–152.
 
68. Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999; 35: 399–407.
 
69. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52–63.
 
70. Jaffee EM. Immunotherapy of cance. Ann N Y Acad Sci 1999; 886: 67–72.
 
71. Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, et al. Antitumor vaccination: Where we stand. Haematologica 2000; 85: 1172–1206.
 
72. Ries S, Korn WM. ONYX-015 Mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5–11.
 
73. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289–298.
 
74. Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, et al. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 2001; 51: 1336–1345.
 
75. Wada Y, Gotoh A, Shirakawa T, Hamada K, Kamidono S. Gene therapy for bladder cancer using adenoviral vector. Mol Urol 2001; 5: 47–52.
 
76. McNeel DG, Disis ML. Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp 2000; 48: 85–93.
 
77. Hoffman DM, Figlin RA. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000; 18: 152–156.
 
78. Cancer vaccine: Antigenics. BioDrugs 2002; 16: 72–74.
 
79. Banerjee D. Genasense (Genta Inc.). Curr Opin Investig Drugs 2001; 2: 574–580.
80. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894–3903.
81. Naitoh J, Witte O, Belldegrun A. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: Bringing together basic scientists and clinicians in the fight against advanced prostate cancer. Cancer Res 1998; 58: 2895–2900.
82. O’Rourke MG, Schmidt CW, O’Rourke TR, Ellem KA. Immunotherapy, including gene therapy, for metastatic melanoma. Aust N Z J Surg 1997; 67: 834–841.
83. Daja MM, Aghmesheh M, Ow KT, Rohde PR, Barrow KD, Russell PJ. β-human chorionic gonadotropin in semen: A marker for early detection of prostate cancer? Mol Urol 2000; 4: 421–427.
84. Sanda MG, Smith DC, Charles LG, Hwang C, Pient KJ, Schlom J, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999; 53: 260–266.
85. Chen Y, Yu DC, Charlton D, Henderson DR. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553–1567.
86. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517–525.
87. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000; 23: 570–580.
88. Sweeney P, Pisters LL. Ad5CMVp53 gene therapy for locally advanced prostate cancer: Where do we stand? World J Urol 2000; 18: 121–124.
89. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829–833.
90. Geary RS, Henry SP, Grillone LR. Fomivirsen: Clinical pharmacology and potential drug interactions. Clin Pharmacokinet 2002; 41: 255–260.
91. Jabs DA, Griffiths PD. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol 2002; 133: 552–556.
92. Weng DE, Usman N. Angiozyme: A novel angiogenesis inhibitor. Curr Oncol Rep 2001; 3: 141–146.
93. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med 2002; 80: 163–175.
94. Murakami P, Pungor E, Files J, Do L, van Rijnsoever R, Vogels R, et al. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum Gene Ther 2002; 13: 909–920.
95. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996; 334: 316–318.